IL162661A0 - Pharmaceutical compositions comprising valsartan and nep inhibitors - Google Patents

Pharmaceutical compositions comprising valsartan and nep inhibitors

Info

Publication number: IL162661A0
Authority: IL; Israel
Prior art keywords: diabetic; disease; renal; pharmaceutically acceptable; heart failure
Prior art date: 2002-01-17

Application number

IL16266103A

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-17

Filing date

2003-01-16

Publication date

2005-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23373410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL162661(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-01-16 Application filed by Novartis Ag filed Critical Novartis Ag

2005-11-20 Publication of IL162661A0 publication Critical patent/IL162661A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL16266103A 2002-01-17 2003-01-16 Pharmaceutical compositions comprising valsartan and nep inhibitors IL162661A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34966002P	2002-01-17	2002-01-17
PCT/EP2003/000415 WO2003059345A1 (fr)	2002-01-17	2003-01-16	Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep

Publications (1)

Publication Number	Publication Date
IL162661A0 true IL162661A0 (en)	2005-11-20

Family

ID=23373410

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16266103A IL162661A0 (en)	2002-01-17	2003-01-16	Pharmaceutical compositions comprising valsartan and nep inhibitors
IL162661A IL162661A (en)	2002-01-17	2004-06-21	Pharmaceutical compositions comprising valsartan and nep inhibitors useful for treating hypertension or heart failure

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL162661A IL162661A (en)	2002-01-17	2004-06-21	Pharmaceutical compositions comprising valsartan and nep inhibitors useful for treating hypertension or heart failure

Country Status (29)

Country	Link
EP (1)	EP1467728B1 (fr)
JP (2)	JP4820056B2 (fr)
KR (2)	KR100984939B1 (fr)
CN (2)	CN1615134A (fr)
AT (1)	ATE370732T1 (fr)
AU (1)	AU2003206738C1 (fr)
BE (1)	BE2016C025I2 (fr)
BR (2)	BR122018015003B8 (fr)
CA (1)	CA2472399C (fr)
CO (1)	CO5600999A2 (fr)
CY (2)	CY1106959T1 (fr)
DE (1)	DE60315795T2 (fr)
DK (1)	DK1467728T3 (fr)
EC (1)	ECSP045190A (fr)
ES (1)	ES2290429T3 (fr)
FR (1)	FR16C0019I2 (fr)
HU (1)	HUS1600024I1 (fr)
IL (2)	IL162661A0 (fr)
LU (1)	LU93074I2 (fr)
MX (1)	MXPA04006917A (fr)
NL (1)	NL300811I2 (fr)
NO (2)	NO333191B1 (fr)
NZ (1)	NZ533968A (fr)
PL (1)	PL212318B1 (fr)
PT (1)	PT1467728E (fr)
RU (1)	RU2334513C3 (fr)
SI (1)	SI1467728T1 (fr)
WO (1)	WO2003059345A1 (fr)
ZA (1)	ZA200405117B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005256634B2 (en) *	2004-06-23	2010-12-09	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1-receptor antagonists
CA2592091A1 (fr)	2004-12-24	2006-06-29	Krka, D.D., Novo Mesto	Composition pharmaceutique solide comprenant du valsartan
MY146830A (en) *	2005-02-11	2012-09-28	Novartis Ag	Combination of organic compounds
WO2007045663A2 (fr) *	2005-10-19	2007-04-26	Novartis Ag	Combinaison de composes organiques
WO2007051007A2 (fr) *	2005-10-28	2007-05-03	Novartis Ag	Combinaison de composes organiques
AR057882A1 (es) *	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (fr) *	2006-03-10	2007-09-20	Novartis Ag	Combinaison de composes organiques
CZ300801B6 (cs) *	2006-06-07	2009-08-12	Helvetia Pharma A.S.	Kompozice s valsartanem v pevných lékových formách
ES2602566T3 (es)	2007-01-12	2017-02-21	Novartis Ag	Proceso para preparar ácido 5-bifenil-4-amino-2-metil pentanoico
GB0708507D0 (en)	2007-05-02	2007-06-13	Queen Mary & Westfield College	Substituted phosphonates and their use
PL2295035T3 (pl) *	2007-11-06	2016-11-30		Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep)
CN101774941A (zh) *	2009-01-13	2010-07-14	浙江九洲药业股份有限公司	2-酰基氨基-3-联苯基丙酸的制备及拆分方法
ES2602902T3 (es)	2009-05-28	2017-02-22	Novartis Ag	Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
CN102448928B (zh)	2009-05-28	2014-10-01	诺华股份有限公司	作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
KR101476937B1 (ko)	2010-08-23	2014-12-24	노파르티스 아게	Ｎｅｐ 억제제의 제조를 위한 중간체의 제조 방법
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
JP6482462B2 (ja) *	2012-08-24	2019-03-13	ノバルティスアーゲー	心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤
TR201808541T4 (tr)	2013-02-14	2018-07-23	Novartis Ag	Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
EP2956445A1 (fr)	2013-02-14	2015-12-23	Novartis AG	Dérivés de l'acide butanoïque bisphényle substitué utiles en tant qu'inhibiteurs de nep présentant une meilleure efficacité in vivo
CN104230865B (zh) *	2013-06-13	2018-01-09	上海翰森生物医药科技有限公司	联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
EP3038653A1 (fr)	2013-08-26	2016-07-06	Novartis AG	Nouvelle utilisation
HUE064634T2 (hu)	2013-08-26	2024-04-28	Novartis Ag	Kardiovaszkuláris betegségek kezelése
WO2016029828A1 (fr) *	2014-08-27	2016-03-03	上海翰森生物医药科技有限公司	Acide crystallin libre, sel hemicalcique et sel d'alpha-phényléthylamine de ahu-377 et son procédé de préparation et son application
WO2016037098A1 (fr) *	2014-09-04	2016-03-10	Concert Pharmaceuticals, Inc.	Sacubitril deutérisé
WO2016037552A1 (fr) *	2014-09-09	2016-03-17	上海翰森生物医药科技有限公司	Composé cristallin bloqueur de récepteur de l'angiotensine-inhibiteur d'endopeptidase neutre (arb-nepi), son procédé de préparation et son application
CN105503760A (zh) *	2014-10-10	2016-04-20	上海翰森生物医药科技有限公司	结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
WO2016074651A1 (fr)	2014-11-14	2016-05-19	Zentiva, K.S.	Procédé de préparation, d'isolation et de purification de formes pharmaceutiquement applicables de ahu-377
WO2016086798A1 (fr) *	2014-12-03	2016-06-09	上海翰森生物医药科技有限公司	Acide libre cristallin d'inhibiteur de l'endopeptidase neutre (nep), polymorphe de sel de calcium de celui-ci, leur procédé de préparation et leurs applications
SI3229799T1 (sl) *	2014-12-08	2019-03-29	Crystal Pharmatech Co., Ltd.	Kristalinične oblike trinatrijevega supramolekularnega kompleksa, ki obsega valsartan in AHU-377, ter njihovi postopki
CN105693543B (zh) *	2014-12-15	2018-08-10	四川海思科制药有限公司	沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104826115A (zh) *	2015-04-19	2015-08-12	浙江巨泰药业有限公司	一种抗心衰药物组合物及其制备方法
CN106138069A (zh) *	2015-04-21	2016-11-23	刘春丽	作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷
JP6576469B2 (ja)	2015-05-11	2019-09-18	ノバルティスアーゲー	心不全の治療のためのサクビトリル−バルサルタンの用量計画
JP2018516267A (ja)	2015-05-29	2018-06-21	ノバルティスアーゲー	代謝性疾患を治療するためのサクビトリルおよびバルサルタン
WO2017006254A1 (fr)	2015-07-08	2017-01-12	Novartis Ag	Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
WO2017012600A1 (fr)	2015-07-20	2017-01-26	Zentiva, K.S.	Composition pharmaceutique contenant du valsartan et du sacubitril et procédés de préparation et de stabilisation correspondants
CN106397248A (zh) *	2015-08-03	2017-02-15	深圳信立泰药业股份有限公司	一种lcz696结晶粉末及其制备方法
EP3355880A1 (fr)	2015-08-28	2018-08-08	Novartis AG	Nouvelle utilisation
WO2017036420A1 (fr) *	2015-09-06	2017-03-09	常州方楠医药技术有限公司	Composition pharmaceutique contenant du valsartan et du sacubitril, et procédé de préparation associé
CN105348209B (zh) *	2015-12-09	2017-12-26	浙江天宇药业股份有限公司	一种抗心衰药lcz696的制备方法
WO2017097275A1 (fr)	2015-12-11	2017-06-15	Zentiva, K.S.	Formes solides d'ester éthylique d'acide (2r,4s)-5-(biphényl-4-yl)-4-[(3-carboxypropionyl)amino]-2-méthylpentanoïque, ses sels et son procédé de préparation
HK1256865A1 (zh)	2016-02-03	2019-10-04	Novartis Ag	有机化合物的盖伦制剂
WO2017134600A1 (fr)	2016-02-03	2017-08-10	Novartis Ag	Nouvelle utilisation d'une combinaison de sacubitril et de valsartan
FI3524250T3 (fi)	2016-10-08	2025-08-29	Wuhan Ll Science & Technology Development Co Ltd	Neutraalia endopeptidaasin (nep) estäjää ja atsilsartaaniesterijohdannaista sisältävä farmaseuttinen koostumus ja sen käyttö sydän- ja verisuonitautien hoitoon
WO2018211479A1 (fr)	2017-05-19	2018-11-22	Lupin Limited	Compositions stabilisées d'inhibiteurs de l'angiotensine ii et d'inhibiteurs de l'endopeptidase neutre, et leur procédé de préparation
US11382866B2 (en)	2017-07-06	2022-07-12	Mankind Pharma Ltd.	Fixed dose pharmaceutical composition of valsartan and sacubitril
EA202090398A1 (ru)	2017-07-28	2020-05-15	Синтон Б.В.	Фармацевтическая композиция, включающая сакубитрил и валсартан
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN110237071B (zh)	2018-03-09	2022-03-22	武汉朗来科技发展有限公司	药物制剂及其应用
CA3110152A1 (fr)	2018-08-23	2020-02-27	Novartis Ag	Nouvelle utilisation pharmaceutique pour le traitement d'une insuffisance cardiaque
WO2020039394A1 (fr)	2018-08-24	2020-02-27	Novartis Ag	Nouvelles combinaisons de médicaments
KR20200020746A (ko)	2020-02-07	2020-02-26	보령제약 주식회사	하이브리드 화합물 및 그 제조방법
WO2021158084A1 (fr) *	2020-02-07	2021-08-12	보령제약 주식회사	Composé hybride et son procédé de préparation
KR20210101164A (ko)	2020-02-07	2021-08-18	보령제약 주식회사	하이브리드 화합물 및 그 제조방법
KR20210120560A (ko)	2020-03-27	2021-10-07	주식회사 유영제약	고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20220091767A (ko)	2020-12-24	2022-07-01	주식회사 보령	사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
WO2024136185A1 (fr)	2022-12-20	2024-06-27	주식회사 티에치팜	Composition pharmaceutique pour la prévention ou le traitement d'une maladie cardiovasculaire, comprenant un inhibiteur du cotransporteur sodium-glucose-2 et un bloqueur du récepteur de l'angiotensine ii
WO2024136184A1 (fr)	2022-12-20	2024-06-27	주식회사 티에치팜	Préparation pharmaceutique orale comprenant un inhibiteur du cotransporteur de sodium-glucose de type 2 et un bloqueur du récepteur de l'angiotensine ii

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1256692A (en) *	1991-02-06	1992-09-07	Schering Corporation	Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) *	1992-01-22	1993-06-08	Ciba-Geigy Corporation	Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (fr) *	1995-02-08	1996-08-09	James R. Powell	Traitement de l'hypertension et de l'insuffisance cardiaque globale
EP1267855A2 (fr) *	2000-04-03	2003-01-02	Bristol-Myers Squibb Company	Inhibiteurs de vasopeptidase pour traiter l'hypertension systolique isolee
AU8576801A (en) *	2000-06-22	2002-01-02	Novartis Ag	Pharmaceutical compositions
PE20020613A1 (es) *	2000-07-19	2002-08-07	Novartis Ag	Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1
US6777443B2 (en) *	2001-05-15	2004-08-17	Novartis Ag	Dipeptide derivatives

2003
- 2003-01-16 PL PL369773A patent/PL212318B1/pl unknown
- 2003-01-16 JP JP2003559507A patent/JP4820056B2/ja not_active Expired - Lifetime
- 2003-01-16 BR BR122018015003A patent/BR122018015003B8/pt not_active IP Right Cessation
- 2003-01-16 CA CA2472399A patent/CA2472399C/fr not_active Expired - Lifetime
- 2003-01-16 ES ES03704413T patent/ES2290429T3/es not_active Expired - Lifetime
- 2003-01-16 PT PT03704413T patent/PT1467728E/pt unknown
- 2003-01-16 CN CNA038022680A patent/CN1615134A/zh active Pending
- 2003-01-16 RU RU2004125178A patent/RU2334513C3/ru active
- 2003-01-16 KR KR1020047011124A patent/KR100984939B1/ko not_active Ceased
- 2003-01-16 CN CN201110029600.7A patent/CN102091330B/zh not_active Expired - Lifetime
- 2003-01-16 BR BRPI0306907A patent/BRPI0306907B8/pt active IP Right Grant
- 2003-01-16 WO PCT/EP2003/000415 patent/WO2003059345A1/fr not_active Ceased
- 2003-01-16 AU AU2003206738A patent/AU2003206738C1/en active Active
- 2003-01-16 KR KR1020107010521A patent/KR20100057704A/ko not_active Ceased
- 2003-01-16 DE DE60315795T patent/DE60315795T2/de not_active Expired - Lifetime
- 2003-01-16 IL IL16266103A patent/IL162661A0/xx unknown
- 2003-01-16 MX MXPA04006917A patent/MXPA04006917A/es active IP Right Grant
- 2003-01-16 NZ NZ533968A patent/NZ533968A/en not_active IP Right Cessation
- 2003-01-16 AT AT03704413T patent/ATE370732T1/de active
- 2003-01-16 DK DK03704413T patent/DK1467728T3/da active
- 2003-01-16 EP EP03704413A patent/EP1467728B1/fr not_active Expired - Lifetime
- 2003-01-16 SI SI200331029T patent/SI1467728T1/sl unknown
2004
- 2004-06-21 IL IL162661A patent/IL162661A/en active Protection Beyond IP Right Term
- 2004-06-28 ZA ZA2004/05117A patent/ZA200405117B/en unknown
- 2004-07-14 EC EC2004005190A patent/ECSP045190A/es unknown
- 2004-08-06 CO CO04076723A patent/CO5600999A2/es active IP Right Grant
- 2004-08-13 NO NO20043380A patent/NO333191B1/no not_active IP Right Cessation
2007
- 2007-10-25 CY CY20071101386T patent/CY1106959T1/el unknown
2011
- 2011-05-25 JP JP2011116928A patent/JP2011207898A/ja not_active Withdrawn
2016
- 2016-05-17 FR FR16C0019C patent/FR16C0019I2/fr active Active
- 2016-05-18 LU LU93074C patent/LU93074I2/fr unknown
- 2016-05-18 BE BE2016C025C patent/BE2016C025I2/nl unknown
- 2016-05-18 NL NL300811C patent/NL300811I2/nl unknown
- 2016-05-18 NO NO2016009C patent/NO2016009I2/no unknown
- 2016-05-18 HU HUS1600024C patent/HUS1600024I1/hu unknown
- 2016-05-18 CY CY2016013C patent/CY2016013I2/el unknown

Also Published As

Publication number	Publication date
PL369773A1 (en)	2005-05-02
BE2016C025I2 (fr)	2022-05-17
EP1467728B1 (fr)	2007-08-22
HUS1600024I1 (hu)	2016-06-28
NO20043380L (no)	2004-10-07
BRPI0306907B1 (pt)	2018-10-30
BRPI0306907B8 (pt)	2021-05-25
AU2003206738C1 (en)	2020-01-30
ATE370732T1 (de)	2007-09-15
MXPA04006917A (es)	2004-12-06
CO5600999A2 (es)	2006-01-31
CY2016013I1 (el)	2016-10-05
IL162661A (en)	2010-11-30
KR100984939B9 (ko)	2024-07-17
BR122018015003B8 (pt)	2021-07-27
CN102091330B (zh)	2015-04-08
DE60315795T2 (de)	2008-06-05
FR16C0019I2 (fr)	2017-12-08
KR20100057704A (ko)	2010-05-31
SI1467728T1 (sl)	2008-02-29
NO333191B1 (no)	2013-03-25
NO2016009I1 (no)	2016-05-18
BR0306907A (pt)	2004-12-21
PT1467728E (pt)	2007-11-14
JP2005514441A (ja)	2005-05-19
PL212318B1 (pl)	2012-09-28
ES2290429T3 (es)	2008-02-16
ZA200405117B (en)	2005-08-31
KR100984939B1 (ko)	2010-10-01
CY1106959T1 (el)	2012-01-25
WO2003059345A1 (fr)	2003-07-24
ECSP045190A (es)	2004-08-27
CA2472399A1 (fr)	2003-07-24
FR16C0019I1 (fr)	2016-06-24
DE60315795D1 (de)	2007-10-04
AU2003206738A1 (en)	2003-07-30
JP4820056B2 (ja)	2011-11-24
LU93074I2 (fr)	2016-07-18
NZ533968A (en)	2006-10-27
KR20040078127A (ko)	2004-09-08
CA2472399C (fr)	2012-02-21
CN1615134A (zh)	2005-05-11
NL300811I2 (fr)	2016-07-27
RU2334513C3 (ru)	2017-10-24
NO2016009I2 (no)	2016-05-18
CY2016013I2 (el)	2016-10-05
DK1467728T3 (da)	2007-12-27
EP1467728A1 (fr)	2004-10-20
BR122018015003B1 (pt)	2018-11-21
RU2334513C2 (ru)	2008-09-27
JP2011207898A (ja)	2011-10-20
AU2003206738B2 (en)	2006-12-21
RU2004125178A (ru)	2005-06-10
CN102091330A (zh)	2011-06-15

Publication	Publication Date	Title
HUS1600024I1 (hu)	2016-06-28	Valsartant és NEP inhibitorokat tartalmazó gyógyszerkészítmények
WO2007106708A3 (fr)	2007-12-27	Combinaison de composes organiques
IL164837A (en)	2013-12-31	Pharmaceuticals containing elisciran, amlododine, and hydrochloride azide and their kit
EP2322174A3 (fr)	2011-07-27	Utilisation combinée de valsartane et bloqueurs du canal de calcium à but thérapeutique
BR0317384A (pt)	2005-11-16	Combinações de valsartan com inibidores de cox-2